Latest Agomab Therapeutics News & Updates

See the latest news and media coverage for Agomab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Agomab Therapeutics (Agomab)

Clinical-stage biopharmaceutical company developing therapies for fibro-inflammatory diseases

agomab.com

Headquarters: Antwerp, Belgium
Founded year: 2017
Company type: Public company
Number of employees: 70–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Agomab Therapeutics (Agomab)

In short: Agomab raised $200 million in its Nasdaq IPO, advanced its Crohn's treatment to Phase 2b, and secured a U.S. patent for its IPF candidate.

Company announcements

September 14 Agomab

Agomab reports positive Phase 1 results for AGMB-447 in IPF patients

The company submitted a Clinical Trial Application for the Phase 2 INSPIRIA study, aiming to initiate treatment later this year.

September 11 Agomab

Agomab appoints Marino Garcia and Dr. Naimish Patel to its Board of Directors

Shareholders approved their appointments and warrant consolidation at the September 11, 2026 meeting.

August 6 Agomab

Agomab reports half-year 2026 financial results and confirms outlook

Cash of €252 million includes $208 million IPO proceeds, extending runway into 2029; FDA aligned on Phase 2b design; topline data from STENOVA OLE and IPF cohort expected soon.

June 23 Agomab

Agomab announces design of NOV-ERA Phase 2b study for ontunisertib

The study targets fibrostenosing Crohn's disease with a novel primary endpoint of endoscopic passability, with dosing expected in H2 2026.

Media coverage

September 14 MarketWatch

Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug

The clinical-stage biopharmaceutical company said that a twice-daily 4.5mg dose of AGMB-447, a treatment for idiopathic pulmonary fibrosis, had a more than 50% reduction of...

August 25 The Globe and Mail

Analysts’ Top Healthcare Picks: Clinuvel Pharmaceuticals (CLVLF), AgomAb Therapeutics NV ADR (AGMB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clinuvel Pharmaceuticals (CLVLF) and AgomAb Therapeutics NV...

August 11 Dagens PS

Agomab fills the coffers with 252 million euros despite zero products.

The Belgian pharmaceutical company has been listed on Nasdaq and the cash will last for several years, but no approved drug exists yet.

August 6 Markets Insider

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in...

Never miss news about Agomab

Track Agomab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Agomab competitors & trending companies

Browse news for competitors to Agomab and other trending companies.